Composite valuation range · conservative $68–$74 / fair $110–$148 / optimistic $202–$220. At $145.47, Within the fair intrinsic-value range.
At publication $170.77 (Jul 2, 2026)
IBD said Guardant Health rose after its Shield colorectal cancer blood test gained UnitedHealth coverage.
Possible impact:May affect Shield adoption, reimbursement access and screening revenue expectations.
Barron's reported UnitedHealth will cover Guardant's Shield colorectal cancer blood screen for about 40 million members.
Possible impact:May affect expectations for Shield adoption, commercial reimbursement, and screening revenue growth.
IBD reported Q1 2026 revenue rose 48% to $301.7 million and Guardant raised its full-year revenue outlook.
Possible impact:May affect expectations for test-volume growth, narrowing losses, and full-year revenue cadence.
The American Cancer Society updated guidelines to include Guardant's Shield blood test as a colorectal screening option.
Possible impact:May affect physician adoption, payer acceptance, and long-term Shield penetration expectations.
Guardant received FDA approval for Guardant360 Liquid CDx, with a much broader genomic footprint than its predecessor.
Possible impact:May affect therapy selection revenue, pricing, and expectations for faster growth in 2027.
Automatically summarized from public sources; for context only, not investment advice.
Data from EODHD, shown in the reporting currency; for reference only, not investment advice.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Coming soonThis section is being filled in — check back soon.
Coming soonThis section is being filled in — check back soon.
